Blockchain Registration Transaction Record

NRx Re-files KETAFREE(TM) ANDA, Advances Safer Ketamine Treatments

NRx Pharmaceuticals re-files ANDA for KETAFREE(TM), advancing preservative-free ketamine treatments for depression and pain. Company also developing NRX-100 and NRX-101.

This development matters because it addresses significant safety concerns in ketamine treatments that affect millions of patients worldwide. Traditional ketamine formulations contain benzethonium chloride, a preservative with documented neurotoxic and cytotoxic properties that could cause long-term harm to patients receiving repeated treatments. With ketamine becoming an increasingly important treatment for depression, chronic pain, and other conditions, safer alternatives are urgently needed. NRx's preservative-free formulations could revolutionize ketamine therapy by eliminating these risks while maintaining therapeutic efficacy. Furthermore, the company's focus on suicidal depression treatments comes at a critical time when mental health crises are rising globally, and existing treatments often fall short. The potential for these developments to provide safer, more effective options for patients with treatment-resistant conditions represents a substantial advancement in psychiatric and pain management care.